Sotagliflozin (brand name Zynquista), will be reviewed by the FDA as a possible adjunct treatment, along with insulin, for type 1 diabetes. If approved, it will be the first oral antidiabetes medication used in combination with insulin in patients diagnosed with type 1 diabetes.  Read more